Advertisement

Robotic Primary RPLND for Stage I Testicular Cancer: a Review of Indications and Outcomes

Abstract

Patients diagnosed with stage I non-seminomatous germ cell tumor (NSGCT) face the task of selecting a management strategy. Whereas these options all offer excellent survival, unfortunately, each has drawbacks. Retroperitoneal lymph node dissection (RPLND) is a major operation with low, but significant risks of bleeding, chylous ascites, and retrograde ejaculation. Platinum-based chemotherapy is associated with a number of long-term side effects, not all of which are quantified, but include secondary malignancy and early cardiovascular disease. While surveillance minimizes the chances of exposure to unnecessary treatment, it is not infrequently salvaged with chemotherapy and requires a compliant patient willing to undergo serial imaging often with ionizing radiation. Although fewer than one-third of patients will relapse without intervention, the current guidelines propose treatment for stage I patients with high-risk features. New developments in minimally invasive techniques may mitigate the harms of RPLND and avoid the side effects of chemotherapy, making it an ideal option for this cohort of patients. Unlike laparoscopic RPLND, which was introduced as a staging procedure and heavily criticized for the advanced skill set required to achieve oncologic equivalence, robotic RPLND may offer the benefits of a minimally invasive technique without a steep learning curve and a true therapeutic operation in experienced hands.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

References

    Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

    1. 1.

      Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. Testicular cancer, version 2 2015. J Natl Compr Cancer Netw. 2015;13(6):772–99.

    2. 2.

      Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF et al. SEER cancer statistics review, 1975–2012, National Cancer Institute. Bethesda, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.

    3. 3.

      Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol. 2003;170:5–11.

    4. 4.

      Shanmugalingam T, Soultati A, Chowdhury S, et al. Global incidence and outcome of testicular cancer. Clin Epidemiol. 2013;5:417–27.

    5. 5.

      Verhoeven RH, Gondos A, Janssen-Heijnen ML, et al. Testicular cancer in Europe and the USA: survival still rising among older patients. Ann Oncol. 2013;24:508–13.

    6. 6.

      Chia VM, Quraishi SM, Devesa SS, et al. International trends in the incidence of testicular cancer, 1973–2002. Cancer Epidemiol Biomarkers Prev. 2010;19:1151–9.

    7. 7.

      McGlynn KA, Devesa SS, Graubard BI, Castle PE. Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol. 2005;23(24):5757–61.

    8. 8.

      Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1054–68. doi:10.1016/j.eururo.2015.07.044.

    9. 9.•

      De Wit R. Optimal management of clinical stage I nonseminoma: new data for patients to consider. J Clin Oncol. 2014;32:3792–3. This article nicely summarizes the surveillance option for stage I NSCGT, and found a 30.6% 5-year relapse rate.

    10. 10.

      Dong P, Liu ZW, Li XD, Li YH, Yao K, Wu S, et al. Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors. Med Oncol. 2013;30(1):494.

    11. 11.

      Kovac E, Stephenson AJ. Management of stage I nonseminomatous germ cell tumors. Urol Clin N Am. 2015;42(3):299–310. doi:10.1016/j.ucl.2015.04.004. Review.

    12. 12.

      Sheinfeld J, Herr HW. Role of surgery in management of germ cell tumor. Semin Oncol. 1998;25:203–9.

    13. 13.•

      Cheney SM, Andrews PE, Leibovich BC, et al. Robot assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients. BJU Int. 2014;115:114–20. This series demonstrates the feasibility of post-chemotherapy RPLND.

    14. 14.

      Rassweiler JJ, Scheitlin W, Heidenreich A, Laguna MP, Janetschek G. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective. Eur Urol. 2008;54:1004–15.

    15. 15.

      Kenney PA, Tuerk IA. Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer. World J Urol. 2008;26:561–9.

    16. 16.

      Albqami N, Janetschek G. Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer. J Endourol. 2005;19(6):683–92. discussion 692.

    17. 17.

      Neyer M, Peschel R, Akkad T, Springer-Stöhr B, Berger A, Bartsch G, et al. Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer. J Endourol. 2007;21(2):180–3.

    18. 18.

      Peschel R, Gettman MT, Neururer R, Hobisch A, Bartsch G. Laparoscopic retroperitoneal lymph node dissection: description of the nerve-sparing technique. Urology. 2002;60(2):339–43. discussion 343.

    19. 19.

      Williams SB, Lau CS, Josephson DY. Initial series of robot-assisted laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer. Eur Urol. 2011;60:1299–302.

    20. 20.

      Poulakis V, Skriapas K, De Vries R, et al. Quality of life after laparoscopic and open retroperitoneal lymph node dissection in clinical stage I nonseminomatous germ cell tumor: a comparison study. Urology. 2006;68:154–60.

    21. 21.

      Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. 2005;23(12):2781–8.

    22. 22.

      Sun M, Abdollah F, Budaüs L, Liberman D, Tian Z, Morgan M, et al. Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study. Ann Surg Oncol. 2011;18(10):2997–3004. doi:10.1245/s10434-011-1722-3.

    23. 23.

      Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol. 2009;181(2):627–32. discussion 632–3.

    24. 24.

      Silva MV, Motamedinia P, Badalato GM, Hruby G, McKiernan JM. Diagnostic radiation exposure risk in a contemporary cohort of male patients with germ cell tumor. J Urol. 2012;187(2):482–6. doi: 10.1016/j.juro.2011.10.028. Erratum in: J Urol. 2012;188(1):334.

    25. 25.

      McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997;15(7):2559–63.

    26. 26.

      Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21:1513–23.

    27. 27.

      Fosså SD, Aass N, Winderen M, Börmer OP, Olsen DR. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol. 2002;13:222–8.

    28. 28.

      Wein AJ, In Kavoussi LR, Campbell MF, Walsh PC. Campbell-Walsh urology. 2012

    29. 29.

      Albers P, Siener R, Krege S et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26(18):2966–72. doi: 10.1200/JCO.2007.12.0899. Erratum in: J Clin Oncol. 2010;28(8):1439.

    30. 30.

      Bianchi G, Beltrami P, Giusti G, Tallarigo C, Mobilio G. Unilateral laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular neoplasm. Eur Urol. 1998;33(2):190–4.

    31. 31.

      Janetschek G, Hobisch A, Peschel R, Hittmair A, Bartsch G. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol. 2000;163(6):1793–6.

    32. 32.

      Nelson JB, Chen RN, Bishoff JT, Oh WK, Kantoff PW, Donehower RC, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology. 1999;54(6):1064–7.

    33. 33.

      Allaf ME, Bhayani SB, Link RE, Schaeffer EM, Varkarakis JM, Shadpour P, et al. Laparoscopic retroperitoneal lymph node dissection: duplication of open technique. Urology. 2005;65(3):575–7.

    34. 34.

      Steiner H, Zangerl F, Stöhr B, Granig T, Ho H, Bartsch G, et al. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol. 2008;180(4):1348–52.

    35. 35.

      Janetschek G, Hobisch A, Höltl L, Bartsch G. Retroperitoneal lymphadenectomy for clinical stage I nonseminomatous testicular tumor: laparoscopy versus open surgery and impact of learning curve. J Urol. 1996;156(1):89–93. discussion 94.

    36. 36.

      Abdel-Aziz KF, Anderson JK, Svatek R, Margulis V, Sagalowsky AI, Cadeddu JA. Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors. J Endourol. 2006;20(9):627–31.

    37. 37.

      Gardner MW, Roytman TM, Chen C, et al. Laparoscopic retroperitoneal lymph node dissection for low-stage cancer: a Washington University update. J Endourol Endourol Soc. 2011;25:1753–7.

    38. 38.

      Hyams ES, Pierorazio P, Proteek O, Sroka M, Kavoussi LR, Allaf ME. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience. J Urol. 2012;187(2):487–92.

    39. 39.

      Davol P, Sumfest J, Rukstalis D. Robotic-assisted laparoscopic retroperitoneal lymph node dissection. Urology. 2006;67:199.

    40. 40.••

      Harris KT, Gorin MA, Ball MW, Pierorazio PM, Allaf ME. A comparative analysis of robotic vs laparoscopic retroperitoneal lymph node dissection for testicular cancer. BJU Int. 2015;116(6):920–3. doi:10.1111/bju.13121. This is the first comparative analysis of robotic and laparoscopic RPLND to evaluate perioperative outcomes and safety.

    41. 41.••

      Pearce SM, Gorin MA et al. Multicenter evaluation of primary robot-assisted laparoscopic RPLND in low-stage non-seminomatous testicular cancer. SUO 2015 abstract, manuscript in preparation. This is a multicenter report on robotic RPLND outcomes.

    42. 42.

      Moore LJ, Wilson MR, Waine E, Masters RS, McGrath JS, Vine SJ. Robotic technology results in faster and more robust surgical skill acquisition than traditional laparoscopy. J Robot Surg. 2015;9(1):67–73. doi:10.1007/s11701-014-0493-9.

    43. 43.

      Buse S, Hach CE, Klumpen P, Alexandrov A, Mager R, Mottrie A, et al. Cost-effectiveness of robot-assisted partial nephrectomy for the prevention of perioperative complications. World J Urol. 2015.

    44. 44.

      Kates M, Ball MW, Patel HD, Gorin MA, Pierorazio PM, Allaf ME. The financial impact of robotic technology for partial and radical nephrectomy. J Endourol. 2015;29(3):317–22. doi:10.1089/end.2014.0559.

    45. 45.

      Donohue JP, Thornhill JA, Foster RS, et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol. 1993;149:237–43.

    46. 46.

      Weissbach L, Boedefeld EA. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol. 1987;138:77–82.

    47. 47.

      Janetschek G, Reissigl A, Peschel R, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular tumor. Urology. 1994;44:382ction.

    Download references

    Author information

    Correspondence to Heather J. Chalfin.

    Ethics declarations

    Conflict of Interest

    Heather J. Chalfin, Wesley Ludwig, Phillip M. Pierorazio, and Mohamad E. Allaf each declare no potential conflicts of interest.

    Human and Animal Rights and Informed Consent

    This article does not contain any studies with human or animal subjects performed by any of the authors.

    Additional information

    This article is part of the Topical Collection on Minimally Invasive Surgery

    Electronic Supplementary Material

    Below is the link to the electronic supplementary material.

    (MP4 352791 kb)

    ESM 1

    (MP4 352791 kb)

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Chalfin, H.J., Ludwig, W., Pierorazio, P.M. et al. Robotic Primary RPLND for Stage I Testicular Cancer: a Review of Indications and Outcomes. Curr Urol Rep 17, 41 (2016) doi:10.1007/s11934-016-0597-z

    Download citation

    Keywords

    • RPLND
    • Robotics
    • Minimally invasive
    • Testis cancer